GET DAILY SIGNALSAkebia Therapeutics (AKBA) Stock Falls -33% as Q3 Earnings Miss Weighs on Shares
Key Takeaways
- AKBA shares fell roughly 33% over the last 30 days, sliding from about $0.79 to approximately $0.53 as investors digested a sharp third-quarter earnings miss.
- Third-quarter 2026 revenue of $36.9 million missed consensus estimates and declined about 37% year over year, pressured by generic competition for Auryxia.
- Vafseo (vadadustat) underlying demand remains solid — patients on therapy grew roughly 140% year over year to about 11,500 — but channel inventory drawdowns weighed on reported net product revenue.
- Positive topline VOCAL trial data showed three-times-weekly vadadustat was non-inferior to ESAs in maintaining hemoglobin, while VOICE results pointed to fewer hospitalizations.
- Analysts at H.C. Wainwright and BTIG trimmed price targets but kept Buy ratings after the quarter, signaling a more cautious near-term outlook.
- For additional detail on valuation and fundamentals, review Akebia's Price Targets, Earnings, and Forecast pages.
Akebia Therapeutics (AKBA) Company Overview and Market Position
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. Founded in 2007 and headquartered in the Cambridge/Waltham, Massachusetts area, the company went public on Nasdaq in March 2014. Its commercial portfolio centers on two products: Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the U.S. in March 2024 for anemia due to chronic kidney disease (CKD) in adults on dialysis, and Auryxia (ferric citrate), used to control serum phosphorus levels in dialysis-dependent CKD and to treat iron deficiency anemia in non-dialysis-dependent CKD.
Vafseo launched commercially in the U.S. in January 2025 and is approved in dozens of countries globally. Akebia's pipeline includes praliciguat for focal segmental glomerulosclerosis (FSGS), AKB-097 for complement-mediated rare kidney diseases, and earlier-stage HIF-based candidates. The company generates revenue through product sales and through partnerships with Mitsubishi Tanabe in Japan, Medice in Europe, and other collaborators. Investors follow AKBA for its exposure to the large CKD market, the commercial ramp of Vafseo, and the development of its rare-kidney-disease franchise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Akebia Therapeutics (AKBA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AKBA has fallen approximately 33%, declining from a closing price of about $0.79 to roughly $0.53. The decline was not gradual: most of the damage occurred in a single session around the November 5 third-quarter earnings release, when the stock dropped from about $0.69 to roughly $0.43, a decline of nearly 39% in one day.
The longer-term trend has been even weaker. Over the last quarter, shares have declined roughly 39%, falling from about $0.87 in mid-August to approximately $0.53. The stock has traded within a wide 52-week range of about $0.36 to $1.89, reflecting sustained volatility and a meaningful repricing of the company's near-term growth prospects.
What Drove AKBA Stock Price in the Last 30 Days
The dominant catalyst behind the recent selloff was Akebia's third-quarter 2026 financial report, released on November 5. The company posted revenue of $36.9 million, missing consensus estimates by a wide margin and down about 37% from $58.8 million a year earlier. Adjusted EPS of a loss of $0.05 also missed expectations, and the company swung to a net loss of about $14.4 million from a small profit a year earlier.
Two factors drove the revenue shortfall. First, Auryxia revenue fell to roughly $20 million from about $42.5 million in the prior-year quarter as generic competition eroded sales. Second, while Vafseo's patient base expanded about 140% year over year, reported Vafseo net product revenue rose only about 3% to $14.8 million because customers drew down inventory ahead of the product's January 1, 2027 TDAPA expiration. Management also cited lower-than-expected average dosing and dialysis adherence.
Partly offsetting the disappointing results, Akebia reported positive topline data from the VOCAL trial, showing that three-times-weekly vadadustat met its primary endpoint of non-inferiority to erythropoiesis-stimulating agents (ESAs) in maintaining hemoglobin. VOICE data presented at a recent conference showed fewer hospitalizations versus ESAs. Following the quarter, analysts at H.C. Wainwright and BTIG lowered their price targets but maintained Buy ratings, reflecting the tension between near-term headwinds and the product's longer-term potential. From what I see, this clinical progress offers some fundamental support amid the revenue pressure.
What Drove AKBA Stock Performance Over the Last Quarter
AKBA's quarterly decline reflects a broader narrative of commercial transition and investor recalibration. Auryxia, once a core revenue driver, lost U.S. exclusivity and has faced expanding generic competition, pressuring a key profit stream. At the same time, Vafseo's commercial trajectory, while encouraging on a patient-count basis, has been complicated by inventory dynamics and the approaching end of its transitional drug add-on payment adjustment (TDAPA) period at the start of 2027.
Sentiment deteriorated through the fall as investors weighed slower-than-expected conversion of patient demand into reported revenue and uncertainty over post-TDAPA pricing and reimbursement. Positive clinical data — including VOCAL topline results and VOICE outcomes — provided fundamental support but were not enough to offset the revenue disappointment and the company's shift back to quarterly losses. The result has been a sustained downward repricing of the stock over the past three months.
AKBA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape AKBA's trajectory. The most immediate is Vafseo's transition past the January 1, 2027 TDAPA expiration, where post-transition pricing and the pace of adoption by large dialysis organizations will be closely watched. Management has guided to continued patient growth, but inventory normalization and reimbursement changes could keep near-term revenue volatile.
Investors should also monitor Auryxia's exposure to further generic erosion, the company's cash position of roughly $159 million, and its stated ability to fund operations for at least two years. Clinical milestones in the rare-kidney-disease pipeline — including Phase 2 programs for praliciguat and AKB-097 — and any refinancing of the senior secured term loan represent additional catalysts. As always, these developments carry execution and regulatory risk, and investors should conduct their own due diligence rather than rely on any single forecast.
Using Tickeron AI Tools for Deeper Analysis
In my own research process, I frequently turn to Tickeron’s AI Trading Bots to test systematic approaches across equities like AKBA. These tools allow me to compare automated strategies with varying timeframes and risk parameters, providing a data-driven complement to fundamental review. The platform covers thousands of tickers and highlights relevant bots based on recent performance, which helps me evaluate how algorithmic models might position around events such as earnings or clinical updates. It serves as a practical way to explore rule-based signals without replacing individual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
AKBA's RSI Oscillator recovers from oversold territory
The RSI Indicator for AKBA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +35.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 64 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.445) is normal, around the industry mean (6.379). P/E Ratio (-3.344) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs for the treatment of anemia and vascular diseases
Industry PharmaceuticalsGeneric
Advertisement